The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kushlinskiĭ N.E.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Gershteĭn E.S.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Investigation of matrix metalloproteinases and their tissue inhibitors in the tumors and peripheral blood of cancer patients. Clinical prospects

Authors:

Kushlinskiĭ N.E., Gershteĭn E.S.

More about the authors

Journal: Laboratory Service. 2013;(1): 25‑38

Read: 1610 times

Download PDF (RU)
Contact the author
Table of contents

INVESTIGATION OF MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS IN THE TUMORS AND PERIPHERAL BLOOD OF CANCER PATIENTS. CLINICAL PROSPECTS
INVESTIGATION OF MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS IN THE TUMORS AND PERIPHERAL BLOOD OF CANCER PATIENTS. CLINICAL PROSPECTS

To cite this article:

Kushlinskiĭ NE, Gershteĭn ES. Investigation of matrix metalloproteinases and their tissue inhibitors in the tumors and peripheral blood of cancer patients. Clinical prospects. Laboratory Service. 2013;(1):25‑38. (In Russ.)

Подписка 2025 Лабораторная служба (Laboratory Service)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
Asse­ssment of the change over time of serum matrix meta­lloproteinases and vascular endo­thelial growth factor in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12-2):13-20
Abstract:

The authors present the results of their observations and the data available in modern literature on investigations of matrix metalloproteinases and their tissue inhibitors in the tumors and serum (plasma) of patients with different cancers, the association of these indices with their major clinical and morphological characteristics and prognosis, as well as the possibilities of their use as goals of targeted therapy.

Keywords:

matrix metalloproteinases
tissue inhibitors of matrix metalloproteinases
human tumors

Authors:

Kushlinskiĭ N.E.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Gershteĭn E.S.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Close metadata

References:

  1. Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views. J Pathol 2008; 214 (3): 283-293.
  2. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-1701.
  3. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92 (8): 827-839.
  4. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13 (8): 781-792.
  5. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004; 6 (2): 96-102.
  6. Liotta L.A., Tryggvason K., Garbisa S. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284 (5751): 67-68.
  7. Furuya M., Ishikura H., Nemori R. et al. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol 2001; 32 (2): 163-168.
  8. Kamat A.A., Fletcher M., Gruman L.M. et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006; 12 (6): 1707-1714.
  9. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25 (1): 9-34.
  10. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18 (5): 1135-1149.
  11. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2010; 1803 (1): 103-120.
  12. Duffy M.J. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2 (4): 613-618.
  13. Zucker S., Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23 (1-2):101-117.
  14. Collins H.M., Morris T.M., Watson S.A. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001; 84 (12): 1664-1670.
  15. Chan C.C., Menges M., Orzechowski H.D. et al. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 2001; 16 (3): 133-140.
  16. Damodharan U., Ganesan R., Radhakrishnan U.C. Expression of MMP2 and MMP9 (gelatinases A and B) in human colon cancer cells. Appl Biochem Biotechnol 2011; 165 (5-6): 1245-1252.
  17. Higashiguchi T., Hotta T., Takifuji K. et al. Clinical impact of matrix metalloproteinase-7 mRNA expression in the invasive front and inner surface of tumor tissues in patients with colorectal cancer. Dis Colon Rectum 2007; 50 (10): 1585-1593.
  18. Hong S.W., Kang Y.K., Lee B. et al. Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011; 27 (3): 133-139.
  19. Hurst N.G., Stocken D.D., Wilson S. et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007; 97 (7): 971-977.
  20. Islekel H., Oktay G., Terzi C. et al. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 2007; 25 (4): 433-441.
  21. Delektorskaya V.V., Perevoshchikov A.G., Golovkov D.A., Kush­linskii N.E. Prognosticheskaya znachimost' ekspressii matriksnykh metalloproteinaz v adenokartsinomakh tolstoi kishki i ikh metastazakh Byul eksper biol med 2007; 143 (4): 434-438.
  22. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2 (3): 161-174.
  23. Nikkola J., Vihinen P., Vuoristo M.S. et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11 (14): 5158-5166.
  24. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115 (Pt 19): 3719-3727.
  25. Jumper C., Cobos E., Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004; 98 (2): 173-177.
  26. Baker E.A., Bergin F.G., Leaper D.J. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000; 53 (6): 307-312.
  27. Duffy M.J., Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37 (7): 541-548.
  28. Janicke F., Prechtl A., Thomssen C. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93 (12): 913-920.
  29. Look M.P., van Putten W.L., Duffy M.J. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94 (2): 116-128.
  30. Schmidt M., Victor A., Bratzel D. et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009; 20 (2): 258-264.
  31. Annecke K., Schmitt M., Euler U. et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008; 45: 31-45.
  32. Fujii T., Obara T., Tanno S. et al. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 1999; 46 (28): 2299-2308.
  33. Herszenyi L., Farinati F., Cardin R. et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 8: 194.
  34. Baker E.A., Leaper D.J. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 2003; 39 (7): 981-988.
  35. Kim T.D., Song K.S., Li G. et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 6: 211.
  36. Fernebro E., Madsen R.R., Ferno M. et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37 (4): 486-491.
  37. Herszenyi L., Istvan G., Cardin R. et al. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008; 17 (5): 438-445.
  38. Zlobec I., Holler S., Tornillo L. et al. Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. Dis Colon Rectum 2009; 52 (6): 1114-1121.
  39. Minoo P., Baker K., Baumhoer D. et al. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol 2010; 41 (1): 70-78.
  40. Langenskiold M., Holmdahl L., Angenete E. et al. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009; 30 (4): 210-220.
  41. Verspaget H.W., Sier C.F., Ganesh S. et al. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 1995; 31A (7-8): 1105-1109.
  42. Begum F.D., Hogdall C.K., Kjaer S.K. et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res 2004; 24 (3b): 1981-1985.
  43. Jacobsen B., Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008; 15 (25): 2559-2573.
  44. Grebenschikov N., Geurts-Moespot A., De Witte H. et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997; 12 (1): 6-14.
  45. Gershtein E.S., Shcherbakov A.M., Kaz'min A.I., Ognerubov N.A., Kushlinskii N.E. Aktivatory plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitor PAI-1 pri rake zheludka. Vopr onkol 2003; 49 (2): 165-169.
  46. Gershtein E.S., Prorokov V.V., Golubchenko O.V., Kushlin­-skii N.E. Aktivatory plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitor PAI-1 pri rake tolstoi kishki: vzaimosvyaz' s osnovnymi kliniko-morfologicheskimi faktorami. Vestn RONTs im N.N. Blokhina RAMN 2002; (2): 31-36.
  47. Gershtein E.S., Medvedeva S.V., Babkina I.V., Kushlin-­skii N.E., Trapeznikov N.N. Aktivatory plazminogena tkanevogo i urokinaznogo tipov i ikh ingibitor PAI-1 v melanomakh i dobrokachestvennykh pigmentnykh novoobrazovaniyakh kozhi. Byul eksp biol med 2001; 132 (7): 71-76.
  48. Gershtein E.S., Kushlinskii N.E., Talaeva Sh.Zh., Sandybaev M.N. Klinicheskaya rol' sistemy aktivatsii plazminogena v opukholyakh cheloveka. Mol meditsina 2007; 1: 4-8.
  49. Gershtein E.S., Gritsaenko E.V., Shcherbakov M.E., Shcherbakov A.M., Ognerubov N.A., Kushlinskii N.E. Faktor rosta endoteliya sosudov i komponenty sistemy aktivatsii plazminogena pri rake i giperplazii endometriya. Vopr onkol; 2003, 49 (6): 725-729.
  50. Gershtein E.S., Kushlinskii N.E. Aktivatory plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitor PAI-1 v opukholyakh cheloveka. Byul eksp biol med 2001; 131 (1): 81-87.
  51. Gershtein E.S., Mamedov U.R., Kostyleva O.I., Kushlin-skii N.E. Immunofermentnoe opredelenie aktivatorov plazminogena i ikh ingibitora v opukholyakh molochnoi zhelezy: svyaz' s kliniko-morfologicheskimi faktorami prognoza. Klin lab diagn 2000; (3): 16-21.
  52. Gershtein E.S., Nikogosyan S.O., Kozachenko V.P., Kushlin-skii N.E. Aktivator plazminogena urokinaznogo tipa v opukholyakh yaichnikov: vzaimosvyaz' s kliniko-morfologicheskimi faktorami i prognozom. Vest RONTs im N.N. Blokhina RAMN 2001; (1): 30-35
  53. Gershtein E.S., Shcherbakov A.M., Goncharov D.Yu. i dr. Komponenty sistemy aktivatsii plazminogena pri rake pishchevoda: vzaimosvyaz' s osnovnymi kliniko-morfologicheskimi faktorami. Vestn RONTs im. N.N. Blokhina RAMN 2002; 4: 20-24.
  54. Kushlinskii N.E., Kazantseva I.A., Gershtein E.S., Khartidi T.Yu., Lyakina L.T., Kalinin A.P. Aktivatory plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitor pri zabolevaniyakh shchitovidnoi zhelezy. Probl endokrinol 2004; 50 (3): 25-29.
  55. Kushlinskii N.E., Yusifov A.I., Gershtein E.S., Solov'ev Yu.N., Trapeznikov N.N. Aktivatory plazminogena i ikh ingibitor v opukholyakh i opukholepodobnykh porazheniyakh kostei. Byul eksp biol med 2001; 132 (2): 180-182.
  56. Gershtein E.S., Batsev A.F., Matyakin E.G., Kushlinskii N.E. Aktivatory plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitor PAI-1 v opukholyakh bol'nykh rakom slizistoi obolochki polosti rta: vzaimosvyaz' s osnovnymi kliniko-morfologicheskimi faktorami. Byul eksp biol med 2010; 149 (3): 323-326.
  57. Gershtein E.S., Prorokov V.V., Kushlinskii N.E. Prognosticheskoe znachenie aktivatorov plazminogena urokinaznogo i tkanevogo tipov i ikh ingibitora PAI-1 v opukholyakh bol'nykh rakom tolstoi kishki: rezul'taty 10-letnego nablyudeniya. Tekhnologii zhivykh sistem 2011; 3: 42-49.
  58. Gershtein E.S., Kushlinskii D.N., Levkina N.V. i dr. Vzaimosvyaz' ekspressii komponentov VEGF-signal'nogo puti i matriksnykh metalloproteinaz v opukholyakh bol'nykh s novoobrazovaniyami yaichnikov. Byul eksper biol med 2011; 151 (4): 431-435.
  59. Gershtein E.S., Levkina N.V., Digaeva M.A. i dr. Matriksnye metalloproteinazy 2, 7, 9 i tkanevoi ingibitor matriksnykh metalloproteinaz 1 tipa v opukholyakh i syvorotke krovi bol'nykh novoobrazovaniyami yaichnikov. Byul eksper biol med 2010; 149 (5): 562-565.
  60. Gershtein E.S., Levkina N.V., Kushlinskii D.N. i dr. Klinicheskie perspektivy issledovaniya matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov u bol'nykh rakom yaichnikov. Vopr biol, med i farmatsevt khimii 2011; 10: 27-34.
  61. Gershtein E.S., Korotkova E.A., Shcherbakov A.M. i dr. Matriksnye metalloproteinazy 7 i 9 i ikh tkanevye ingibitory 1 i 4 tipa v opukholyakh i plazme krovi bol'nykh rakom tolstoi kishki. Byul eksper biol med 2007; 143 (3): 438-441.
  62. Gershtein E.S., Korotkova E.A., Prorokov V.V., Kushlinskii N.E. Matriksnye metalloproteinazy 2, 3, 13 i ikh tkanevoi ingibitor 2-go tipa v opukholyakh i plazme krovi bol'nykh rakom tolstoi kishki. Byul eksper biol med 2008; 145 (3): 337-341.
  63. Korotkova E.A., Gershtein E.S., Prorokov V.V., Kushlinskii N.E. Tkanevoi ingibitor matriksnykh metalloproteinaz 1 tipa (TIMP-1) pri rake tolstoi kishki: vzaimosvyaz' s kliniko-morfologicheskimi faktorami. Vopr onkol 2009; 55 (2): 171-176.
  64. Korotkova E.A., Gershtein E.S., Prorokov V.V., Kushlinskii N.E. Klinicheskie perspektivy issledovaniya matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov u bol'nykh rakom tolstoi kishki. Vopr biol, med i farmatsevt khimii 2012; 10: 41-46.
  65. Gershtein E.S., Li S., Ryabov A.B. i dr. Sravnitel'noe immunofermentnoe issledovanie matriksnykh metalloproteinaz-2, -7, -9 i ikh tkanevogo ingibitora 2 tipa v opukholyakh i plazme krovi bol'nykh rakom zheludka. Byul eksper biol med 2009; 148 (12): 660-663.
  66. Katunina A.I., Gershtein E.S., Ermilova V.D. i dr. Matriksnye metalloproteinazy 2, 7 i 9 v opukholyakh i syvorotke krovi bol'nykh rakom molochnoi zhelezy. Byul eksper biol med 2011; 151 (3): 334-338.
  67. Kushlinskii N.E., Solov'ev Yu.N., Babkina I.V. i dr. Matriksnye metalloproteinazy 2, 7, 9 i tkanevoi ingibitor matriksnykh metalloproteinaz 1-go tipa v syvorotke krovi bol'nykh opukholyami kostei. Byul eksper biol med 2010; 149 (2): 194-196.
  68. Kushlinskii N.E., Gershtein E.S., Korotkova E.A., Prorokov V.V. Prognosticheskoe znachenie assotsiirovannykh s opukhol'yu proteaz pri rake tolstoi kishki. Byul eksper biol med 2012; 154 (9): 350-355.
  69. Hu X.X., Li L., Li D.R. et al. Inhibitory effects of antisense MMP-9 oligodeoxynucleotides on invasiveness and adherence of ovarian cancer cells. Zhonghua Zhong Liu Za Zhi 2006; 28 (9): 662-665.
  70. Wang F.Q., Smicun Y., Calluzzo N., Fishman D.A. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol Cancer Res 2006; 4 (11): 831-841.
  71. Wu M., Shi Y., Xi L. et al. Construction of antisense MT1-MMP vector and its inhibitory effects on invasion of human ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 2005; 25 (6): 715-717.
  72. Wu M., Xu G., Xi L. et al. Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells. Oncol Rep 2006; 15 (2): 501-505.
  73. Gershtein E.S., Kushlinskii N.E. Sovremennye predstavleniya o mekhanizmakh peredachi signalov faktorov rosta kak osnova effektivnoi molekulyarno-napravlennoi protivoopukholevoi terapii. Vopr biol, med i farmatsevt khimii 2007; 1: 4-9.
  74. Ellerbroek S.M., Halbleib J.M., Benavidez M., Warmka J.K., Wattenberg E.V., Stack M.S., Hudson L.G. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001; 61 (5): 1855-1861.
  75. Nicosia S.V., Bai W., Cheng J.Q., Coppola D., Kruk P.A. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003; 17 (4): 927-943.
  76. Zhou H.Y., Wong A.S. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147 (5): 2557-2566.
  77. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66 (7): 3912-3920
  78. Ulku A.S., Schafer R., Der C.J. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Mol Cancer Res 2003; 1 (14): 1077-1088.
  79. Lau M.T., Wong A.S., Leung P.C. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 2010; 151 (7): 2985-2993.
  80. Symowicz J., Adley B.P., Gleason K.J., Johnson J.J., Ghosh S., Fishman D.A., Hudson L.G., Stack M.S. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007; 67 (5): 2030-2039.
  81. Sawada K., Radjabi A.R., Shinomiya N., Kistner E., Kenny H., Becker A.R., Turkyilmaz M.A., Salgia R., Yamada S.D., Vande Woude G.F. et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67 (4): 1670-1679.
  82. Shield K., Riley C., Quinn M.A., Rice G.E., Ackland M.L., Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 2007; 6: 11.
  83. Celiker M.Y., Wang M., Atsidaftos E., Liu X., Liu Y.E., Jiang Y., Valderrama E., Goldberg I.D., Shi Y.E. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 2001; 20 (32): 4337-4343.
  84. Brand K., Baker A.H., Perez-Canto A., Possling A., Sacharjat M., Geheeb M., Arnold W. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 2000; 60 (20): 5723-5730.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.